Tumor markers, such as the estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2, are routinely employed to assess invasive breast cancers, and in cases of advanced disease, circulating tumor markers CA15-3/BR27-29 or carcinoembryonic antigen may be used to monitor response to therapies [3]. This evidence concerns the gene PGR and neoplasm.